不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel:ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Predictive Factors for Early Immune Recovery in NHL Patients after Autologous Transplantation: A Multicenter Prospective Study.
Predictive Factors for Early Immune Recovery in NHL Patients after Autologous Transplantation: A Multicenter Prospective Study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
自体造血干细胞移植(AHCT)后第+15天绝对淋巴细胞计数(ALC-15)≥ 0.5 × 10 9 /L所表现的早期淋巴细胞恢复与更好的结局相关。这项前瞻性多中心研究旨在阐明178例非霍奇金淋巴瘤患者AHCT后与ALC-15 ≥ 0.5 × 10 9 /L相关的因素。以峰值血CD34 +细胞数 > 45 × 10 6 /L所表现的动员能力与更高的ALC-15水平相关(p = 0.020)。
此外,输注移植物中CD3 + CD4 + T细胞数量 > 31.8 × 10 6 /kg可预测ALC-15 ≥ 0.5 × 10 9 /L(p < 0.001)。
同时,输注移植物CD3 + CD8 + T细胞数量 > 28.8 × 10 6 /kg(p = 0.017)和NK细胞 > 4.4 × 10 6 /kg与更高的ALC-15相关(p < 0.001)。ALC-15 ≥ 0.5 × 10 9 /L的患者AHCT后两年无进展生存率显著更好(74% vs. 57%, p = 0.027)。ALC-15较高患者的五年OS为78%,而ALC-15较低患者为60%(p = 0.136)。
总之,CD34 +细胞的动员能力和移植物细胞内容的详细指标是预测ALC-15 ≥ 0.5 × 10 9 /L的预后工具,而ALC-15 ≥ 0.5 × 10 9 /L与NHL患者AHCT后更好的结局相关。
Early lymphocyte recovery as manifested by an absolute lymphocyte count at d+15 (ALC-15) ≥ 0. 5 × 10 9 /L after autologous hematopoietic stem cell transplantation (AHCT) has been associated with a better outcome. This prospective multicenter study aimed to clarify factors associated with ALC-15 ≥ 0. 5 × 10 9 /L after AHCT among 178 patients with non-Hodgkin lymphoma. The mobilization capacity, as manifested by peak blood CD34 + cell numbers > 45 × 10 6 /L correlated with higher ALC-15 levels ( p = 0. 020).
In addition, the amount of CD3 + CD4 + T cells > 31. 8 × 10 6 /kg in the infused graft predicted ALC-15 ≥ 0. 5 × 10 9 /L ( p < 0. 001). Also, the number of infused graft CD3 + CD8 + T cells > 28. 8 × 10 6 /kg ( p = 0. 017) and NK cells > 4. 4 × 10 6 /kg was linked with higher ALC-15 ( p < 0. 001). The two-year progression-free survival after AHCT was significantly better in patients with ALC-15 ≥ 0.
5 × 10 9 /L (74 vs. 57%, p = 0. 027). The five-year OS in patients with higher ALC-15 was 78% vs. 60% in those with lower ALC-15 ( p = 0. 136). To conclude, the mobilization capacity of CD34 + cells and detailed measures of graft cellular content mark prognostic tools that predict ALC-15 ≥ 0. 5 × 10 9 /L, which is associated with a better outcome in NHL patients after AHCT.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。